{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T10:35:07Z","timestamp":1786703707433,"version":"build-2736575974"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"S\u00f8rlandet Sykehus HF"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>For opioid use disorder (OUD), pharmacological therapy using methadone or buprenorphine, plus psychosocial support, is the most effective opioid agonist treatment (OAT). Long-acting injectable buprenorphine (LAIB) is the newest buprenorphine formulation. This study evaluated LAIB within a naturalistic clinical setting, compared with standard OAT (sublingual buprenorphine and methadone).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This observational study included patients from an OAT outpatient clinic in Agder County, Norway. Data were extracted from hospital medical records in May 2022. The cohort was followed up in February 2025. Medication-group transitions and outcomes were assessed by examining switching, discontinuation, mortality, and illicit substance use over three years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study included 424 patients. The LAIB group was significantly younger than the standard OAT groups. During the study period, 13.2% of patients switched medications, increasing the LAIB group from 17% to 22%. Comparable proportions of patients experienced negative outcomes: 10% discontinued treatment, and 4% died. At follow\u2011up, illicit substance-use problems were less frequent in the sublingual buprenorphine group than the other groups, a finding that appears to have been influenced by differential attrition. Baseline substance use was the strongest predictor of illicit substance use at follow\u2011up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The LAIB group slightly increased during the study period. Transitions between medication groups appeared to yield better substance-use outcomes at follow-up in the sublingual buprenorphine group, compared to in other groups. Baseline substance use was the strongest predictor of illicit use at follow\u2011up, suggesting that individual clinical characteristics may contribute more to outcomes than the specific medication pathway.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>Clinical trial: number not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13722-026-00711-0","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T01:44:51Z","timestamp":1786671891000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Medication transitions and predictors of illicit substance use during opioid agonist treatment: a three-year follow-up study"],"prefix":"10.1186","volume":"21","author":[{"given":"Nina","family":"Jobling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Mj\u00e5land","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Clausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Taraldsen","family":"Heldal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitte","family":"Thylstrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John-K\u00e5re","family":"Vederhus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"711_CR1","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.drugalcdep.2018.12.018","volume":"197","author":"ML Mittal","year":"2019","unstructured":"Mittal ML, et al. Opioid agonist treatment and the process of injection drug use initiation. Drug Alcohol Depend. 2019;197:354\u201360.","journal-title":"Drug Alcohol Depend"},{"issue":"11","key":"711_CR2","doi-asserted-by":"publisher","first-page":"e1002973","DOI":"10.1371\/journal.pmed.1002973","volume":"16","author":"C Marks","year":"2019","unstructured":"Marks C, et al. Opioid agonist treatment scale-up and the initiation of injection drug use: a dynamic modeling analysis. PLoS Med. 2019;16(11):e1002973.","journal-title":"PLoS Med"},{"issue":"1","key":"711_CR3","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1186\/s12913-019-4282-z","volume":"19","author":"AB Bech","year":"2019","unstructured":"Bech AB, et al. Mortality and causes of death among patients with opioid use disorder receiving opioid agonist treatment: a national register study. BMC Health Serv Res. 2019;19(1):440.","journal-title":"BMC Health Serv Res"},{"issue":"6","key":"711_CR4","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/S2215-0366(23)00095-0","volume":"10","author":"L Degenhardt","year":"2023","unstructured":"Degenhardt L, et al. Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studies. Lancet Psychiatry. 2023;10(6):386\u2013402.","journal-title":"Lancet Psychiatry"},{"key":"711_CR5","doi-asserted-by":"publisher","first-page":"104748","DOI":"10.1016\/j.drugpo.2025.104748","volume":"138","author":"R Ivasiy","year":"2025","unstructured":"Ivasiy R, et al. Retention and dropout from sublingual and extended-release buprenorphine treatment: A comparative analysis of data from a nationally representative sample of commercially-insured people with opiod use disorder in the United States. Int J Drug Policy. 2025;138:104748.","journal-title":"Int J Drug Policy"},{"key":"711_CR6","volume-title":"Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence","author":"World Health Organization","year":"2009","unstructured":"World Health Organization. Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence. WHO: Geneva; 2009."},{"issue":"3","key":"711_CR7","doi-asserted-by":"publisher","first-page":"37517","DOI":"10.52965\/001c.37517","volume":"10","author":"S Poliwoda","year":"2022","unstructured":"Poliwoda S, et al. Buprenorphine and its formulations: a comprehensive review. Health Psychol Res. 2022;10(3):37517.","journal-title":"Health Psychol Res"},{"issue":"3","key":"711_CR8","doi-asserted-by":"publisher","first-page":"98","DOI":"10.18773\/austprescr.2025.028","volume":"48","author":"HH Wilson","year":"2025","unstructured":"Wilson HH, Kanck J. Medicines used in the treatment of opioid dependence. Australian Prescriber. 2025;48(3):98.","journal-title":"Australian Prescriber"},{"key":"711_CR9","unstructured":"European Medicines Agency. Buvidal (buprenorphine) An overview of Buvidal and why it is authorised in the EU. 2018 [cited December 17, 2025; Available from: https:\/\/www.ema.europa.eu\/en\/search?keywords=anyword&search_api_fulltext=buvidal&f%5B0%5D=ema_search_entity_is_document%3ADocument&page=1."},{"key":"711_CR10","unstructured":"Nesse L, et al. Status report 2023: twenty-five years of opioid agonist treatment (OAT) [Statusrapport 2023: Tjuefem \u00e5r med legemiddelassistert rehabilitering (LAR)]. Oslo: Senter for rus- og avhengighetsforskning (SERAF), University of Oslo; 2024."},{"key":"711_CR11","unstructured":"United Nations Office on Drugs and. Crime - (UNDDC), World Drug Report 2024. Vienna; 2024."},{"issue":"1\u20133","key":"711_CR12","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.drugalcdep.2007.11.003","volume":"94","author":"T Clausen","year":"2008","unstructured":"Clausen T, Anchersen K, Waal H. Mortality prior to, during and after opioid maintenance treatment (OMT): a national prospective cross-registry study. Drug Alcohol Depend. 2008;94(1\u20133):151\u20137.","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"711_CR13","doi-asserted-by":"publisher","first-page":"e090736","DOI":"10.1136\/bmjopen-2024-090736","volume":"15","author":"C Montgomery","year":"2025","unstructured":"Montgomery C, et al. Investigating outcomes in a substance use treatment provider: a cross-sectional comparison of long-acting injectable buprenorphine and oral medication for opioid use disorder. BMJ open. 2025;15(2):e090736.","journal-title":"BMJ open"},{"issue":"12","key":"711_CR14","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1038\/s41380-018-0094-5","volume":"24","author":"J Ma","year":"2019","unstructured":"Ma J, et al. Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis. Mol Psychiatry. 2019;24(12):1868\u201383.","journal-title":"Mol Psychiatry"},{"issue":"12","key":"711_CR15","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1080\/17581869.2025.2555164","volume":"15","author":"N Lintzeris","year":"2025","unstructured":"Lintzeris N, Dunlop AJ. Buvidal\/Brixadi\u2013a long-acting injectable buprenorphine formulation for the treatment of opioid dependence. Pain Manage. 2025;15(12):897\u2013910.","journal-title":"Pain Manage"},{"issue":"3","key":"711_CR16","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1136\/ebm1184","volume":"16","author":"T Clausen","year":"2011","unstructured":"Clausen T. Mortality is reduced while on opiate maintenance treatment, but there is a temporary increase in mortality immediately after starting and stopping treatment, a finding that may vary by setting. BMJ Evidence-Based Med. 2011;16(3):94\u20135.","journal-title":"BMJ Evidence-Based Med"},{"key":"711_CR17","doi-asserted-by":"crossref","unstructured":"Tran LT, et al. The association between mental disorders and treatment retention among people with opioid use disorder receiving opioid agonist treatment: a systematic review and meta-analysis. Drug Alcohol Depend. 2025;274:112768.","DOI":"10.1016\/j.drugalcdep.2025.112768"},{"issue":"2","key":"711_CR18","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/bcp.12051","volume":"77","author":"J Bell","year":"2014","unstructured":"Bell J. Pharmacological maintenance treatments of opiate addiction. Br J Clin Pharmacol. 2014;77(2):253\u201363.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"711_CR19","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1177\/10398562241295872","volume":"33","author":"J McMaster","year":"2025","unstructured":"McMaster J, Abeysundera H. Effectiveness of long-acting buprenorphine\u2013A systematic review. Australasian Psychiatry. 2025;33(2):235\u201348.","journal-title":"Australasian Psychiatry"},{"issue":"6","key":"711_CR20","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1177\/10398562221120365","volume":"30","author":"C Nayer","year":"2022","unstructured":"Nayer C, et al. Comparison of the characteristics of patients treated with sublingual vs. long-acting injectable buprenorphine formulations for treatment of opioid use disorder: A retrospective cohort study. Australasian Psychiatry. 2022;30(6):754\u20138.","journal-title":"Australasian Psychiatry"},{"key":"711_CR21","unstructured":"Watten RG, Waal H. Need for renewal? Detoxification traditions in norway examined through a pilot study of Ultra-Rapid Opioid Detoxification (UROD) [Behov for fornyelse? Avrusingstradisjonene i Norge belyst gjennom en forunders\u00f8kelse av ultra-rask opioidavrusing (UROD)]. Senter for rus- og avhengighetsforskning (SERAF) - UiO; Oslo; 2001."},{"key":"711_CR22","unstructured":"Hansen MB, Korn\u00f8r H, Waal H. Contributions to the evaluation of opioid agonist treatment in Norway [Bidrag til evaluering av legemiddelassistert rehabilitering i Norge]. 2004, SKR-rapport 7\/2004: Seksjon for kliniske rusmiddelproblemer; Oslo."},{"key":"711_CR23","unstructured":"Waal H, et al. Is quality improvement now more important than capacity development? Status report 2016 [Er kvalitetsforbedring n\u00e5 viktigere enn kapasitetsutvikling? Statusrapport 2016]. Senter for rus- og avhengighetsforskning (SERAF); Oslo; 2017."},{"key":"711_CR24","unstructured":"The Norwegian Directorate of Health. New national guideline for treatment of opioid dependence [Ny nasjonal retningslinje for behandling ved opioidavhengighet]. 2022 [cited 2026 February 25, 2026]; Available from: https:\/\/www.helsedirektoratet.no\/retningslinjer\/behandling-ved-opioidavhengighet."},{"key":"711_CR25","unstructured":"Helse- og omsorgsdepartementet. Regulations on opioid agonist treatment (OAT Regulations) [Forskrift om legemiddelassistert rehabilitering (LAR-forskriften)], Helse og omsorgsdepartementet, 2010, LOVDATA: Oslo."},{"key":"711_CR26","volume-title":"The ICD-10 classification of mental and behavioural disorders [ICD-10: psykiske lidelser og atferdsforstyrrelser: kliniske beskrivelser og diagnostiske retningslinjer]. The ICD-10 classification of mental and behavioural disorders","author":"World Health Organization","year":"1999","unstructured":"World Health Organization. The ICD-10 classification of mental and behavioural disorders [ICD-10: psykiske lidelser og atferdsforstyrrelser: kliniske beskrivelser og diagnostiske retningslinjer]. The ICD-10 classification of mental and behavioural disorders. Oslo: Universitetsforl; 1999."},{"issue":"3","key":"711_CR27","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1080\/00401706.1964.10490181","volume":"6","author":"OJ Dunn","year":"1964","unstructured":"Dunn OJ. Multiple comparisons using rank sums. Technometrics. 1964;6(3):241\u201352.","journal-title":"Technometrics"},{"key":"711_CR28","doi-asserted-by":"publisher","first-page":"108764","DOI":"10.1016\/j.drugalcdep.2021.108764","volume":"225","author":"JR Morgan","year":"2021","unstructured":"Morgan JR, et al. Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort. Drug Alcohol Depend. 2021;225:108764.","journal-title":"Drug Alcohol Depend"},{"key":"711_CR29","doi-asserted-by":"publisher","first-page":"209348","DOI":"10.1016\/j.josat.2024.209348","volume":"162","author":"MR Daglish","year":"2024","unstructured":"Daglish MR, Hayllar JS, McDonough M. An Australian retrospective observational cohort comparison of the use of long-acting injectable buprenorphine products. J Subst Use Addict Treat. 2024;162:209348.","journal-title":"J Subst Use Addict Treat"},{"key":"711_CR30","doi-asserted-by":"publisher","first-page":"111032","DOI":"10.1016\/j.drugalcdep.2023.111032","volume":"254","author":"A Iacono","year":"2024","unstructured":"Iacono A, et al. Characteristics, treatment patterns and retention with extended-release subcutaneous buprenorphine for opioid use disorder: a population-based cohort study in Ontario, Canada. Drug Alcohol Depend. 2024;254:111032.","journal-title":"Drug Alcohol Depend"},{"issue":"10","key":"711_CR31","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1111\/add.70105","volume":"120","author":"C Deng","year":"2025","unstructured":"Deng C, et al. A comparative study of treatment retention in opioid use disorder: Subcutaneous injectable versus sublingual buprenorphine. Addiction. 2025;120(10):2127\u201333.","journal-title":"Addiction"},{"issue":"11","key":"711_CR32","doi-asserted-by":"publisher","first-page":"3139","DOI":"10.1111\/add.15514","volume":"116","author":"C Bharat","year":"2021","unstructured":"Bharat C, et al. The effect of person, treatment and prescriber characteristics on retention in opioid agonist treatment: a 15-year retrospective cohort study. Addiction. 2021;116(11):3139\u201352.","journal-title":"Addiction"},{"key":"711_CR33","doi-asserted-by":"publisher","first-page":"109932","DOI":"10.1016\/j.drugalcdep.2023.109932","volume":"248","author":"V Mocanu","year":"2023","unstructured":"Mocanu V, et al. Opioid agonist therapy switching among individuals with prescription-type opioid use disorder: Secondary analysis of a pragmatic randomized trial. Drug Alcohol Depend. 2023;248:109932.","journal-title":"Drug Alcohol Depend"},{"key":"711_CR34","unstructured":"Bukten A, et al. Status report 2024. Senter for rus- og avhengighetsforskning (SERAF); Oslo; 2025."},{"key":"711_CR35","doi-asserted-by":"publisher","first-page":"103492","DOI":"10.1016\/j.drugpo.2021.103492","volume":"100","author":"M Farrell","year":"2022","unstructured":"Farrell M, et al. Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence. Int J Drug Policy. 2022;100:103492.","journal-title":"Int J Drug Policy"},{"key":"711_CR36","doi-asserted-by":"publisher","first-page":"209155","DOI":"10.1016\/j.josat.2023.209155","volume":"154","author":"D Rutrick","year":"2023","unstructured":"Rutrick D, et al. 18-Month efficacy and safety analysis of monthly subcutaneous buprenorphine injection for opioid use disorder: Integrated analysis of phase 3 studies. J Subst Use Addict Treat. 2023;154:209155.","journal-title":"J Subst Use Addict Treat"},{"issue":"8","key":"711_CR37","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1111\/add.14636","volume":"114","author":"M Frost","year":"2019","unstructured":"Frost M, et al. Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out\u2010patients with opioid use disorder. Addiction. 2019;114(8):1416\u201326.","journal-title":"Addiction"},{"key":"711_CR38","doi-asserted-by":"publisher","first-page":"108005","DOI":"10.1016\/j.drugalcdep.2020.108005","volume":"212","author":"H Dong","year":"2020","unstructured":"Dong H, et al. Changes in substance use in relation to opioid agonist therapy among people who use drugs in a Canadian setting. Drug Alcohol Depend. 2020;212:108005.","journal-title":"Drug Alcohol Depend"},{"key":"711_CR39","unstructured":"Lillevold PH, et al. Status report 2025 \u2013 developing a new and revised status report [Statusrapport 2025 - Mot en ny og revidert statusrapport]. Senter for rus- og avhengighetsforskning (SERAF); Oslo; 2026."}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-026-00711-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-026-00711-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-026-00711-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T10:05:53Z","timestamp":1786701953000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13722-026-00711-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["711"],"URL":"https:\/\/doi.org\/10.1186\/s13722-026-00711-0","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"assertion":[{"value":"23 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Regional Committee for Medical and Health Research Ethics, Health Region South\u2011East (No. 257930), classified the project as quality assurance, and waived the requirement for ethical approval.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data processing was reviewed and approved by the Norwegian Centre for Research Data (NSD; No. 401093), acting as the institution\u2019s Data Protection Service, with an updated approval in 2024 to ensure continued compliance with the General Data Protection Regulation (GDPR). In accordance with GDPR and national regulations, NSD confirmed that individual informed consent was not required.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"61"}}